Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable […]
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients12.1 months median OS in intention-to-treat MDS […]
Hooker Furniture Reports Preliminary Results for First Quarter During February-April COVID Crisis
MARTINSVILLE, Va., June 12, 2020 (GLOBE NEWSWIRE) — Hooker Furniture Corporation (NASDAQ-GS: HOFT) today reported its preliminary financial results for […]
Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced […]
Qingke Announces New Chief Operating Officer
SHANGHAI, China, June 12, 2020 (GLOBE NEWSWIRE) — Q&K International Group Limited (NASDAQ: QK) (“Qingke” or the “Company”), a leading […]
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
-Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for […]
Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease
– 5 of 8 (63%) Efficacy Evaluable Patients Achieved a Hemoglobin Increase of ≥1.0 g/dL From Baseline –– Safety Profile […]
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated […]
Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress
Pivotal AUTO1 study in adult ALL patients enrolling– AUTO1 continued favorable safety profile and high level of clinical activity, pivotal […]
BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress
CAMBRIDGE, Mass. and BEIJING, China, June 12, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology […]
